ClinicalTrials.gg
RecruitingNCT07539844ConFeRUpdated Sep 14, 2026

Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

An observational study in Ovarian Cancer, sponsored by AbbVie. Recruiting at 12 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ovarian Neoplasms by AbbVie — 6 open to participants now, 9 under way, 1 of them phase 3. Ovarian Neoplasms · AbbVie.

Started
2026
with 3 others
Observational
3 of 28
3 open now
Registered
26th of 28
by date

Among the 28 studies in Ovarian Neoplasms by AbbVie, this one is one of 4 that started in 2026, is one of 3 observational ones, and was the 26th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 28 studies in Ovarian Neoplasms by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ovarian Neoplasms by AbbVie, or all of them as a file.
02

Study summary

Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.

Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected. This is a retrospective study and testing will be performed prospectively on archived samples.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 1 Year.

There is no additional burden for participants in this trial.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Cancer
  • Elahere
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is surgical or biopsy sample from an adult female with tumoral High Grade Serous Ovarian Cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgical or samples (Formalin Fixed Paraffin Embedded [FFPE]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses.
  • Archival specimens should not be older than 5 years in order to control quality of the samples.
  • Specimens containing a minimum of 100 viable tumor cells.

Exclusion criteria

Exclusion Criteria:

  • Surgical or samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section).
  • Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy.
  • Tissue obtained through fine needle aspirations or liquid specimens, or ascites
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • Banked Tissue Samples Undergoing Chart Review

    Banked tissue samples undergoing chart review and retrospective folate receptor alpha (FRa) testing of tissue biopsies.

06

What researchers measure

Primary outcomes

  1. Folate Receptor Alpha (FRa) Overexpression Immunohistochemistry (IHC)in Each Participating Sites (Local and Central)

    FRa positive overexpression is defined as: tumor cell membrane staining of at least 75% with a 2+ and/or 3+ staining, or FRa negative as: tumor cell membrane staining of less than 75% with a 2+ and/or 3+ staining.

    Time frame: Up to Approximately 1 Year

07

Study locations

12 of 12 sites recruiting
  • Biomakers /ID# 280318
    Buenos Aires, Buenos Aires 1119, Argentina
    Recruiting
  • Hospital Italiano de Buenos Aires /ID# 280315
    Buenos Aires, Buenos Aires 1181, Argentina
    Recruiting
  • Instituto Alexander Fleming /ID# 281479
    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1426, Argentina
    Recruiting
  • A.C. Camargo Cancer Center - Rua Professor Antonio Prudente /ID# 280407
    São Paulo, São Paulo 01509-900, Brazil
    Recruiting
  • Brazil - Generic Institution /ID# 287000
    São Paulo, Brazil
    Recruiting
  • Toronto General Hospital-University Health Network /ID# 282521
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
  • Fundacion Para La Investigacion Clinica Y Molecular Aplicada Del Cancer - Ficmac /ID# 282327
    Bogotá, Bogota D.C. 110111, Colombia
    Recruiting
  • Instituto Nacional De Cancerologia /ID# 282312
    Bogota, Cundinamarca 110411, Colombia
    Recruiting
  • Fundacion Valle Del Lili /ID# 280794
    Cali, Valle del Cauca Department 760016, Colombia
    Recruiting
  • Mexico - Generic Institution /ID# 281927
    Mexico City, Mexico
    Recruiting
  • Mexico - Generic Institution /ID# 281928
    Mexico City, Mexico
    Recruiting
  • Mexico - Generic Institution /ID# 281930
    Mexico City, Mexico
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 20, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07539844
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Jul 2, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Rebekah Taylor
Contact
rebekah.taylor@abbvie.com
(847) 937-8000
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion